FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMIRA Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MIRA
MIRA Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for MIRA Pharmaceuticals, Inc. (MIRA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMIRA
MIRA
MIRA Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MIRA
  1. Home
  2. Stocks
  3. MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc.

🇺🇸MIRA•NASDAQ

MIRA Pharmaceuticals, Inc.

🇺🇸MIRA•NASDAQ
Market cap
$24.84M
Sentiment

Your view on MIRA

Mkt Cap
$24.84M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About MIRA Pharmaceuticals, Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Erez Aminov
Headquarters
855 North Wolfe Street, Baltimore, MD, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Erez Aminov
Headquarters
855 North Wolfe Street, Baltimore, MD, US
Description

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.

The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.

It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for MIRA Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. MIRA last traded at $0.59; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for MIRA Pharmaceuticals, Inc.. Starting points for MIRA Pharmaceuticals, Inc.: EPS -$0.23, beta 1.49 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for MIRA Pharmaceuticals, Inc.. Trailing twelve-month EPS for MIRA Pharmaceuticals, Inc. stands at -$0.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Buy2 ratings
  • Strong Buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.03-$0.04-$0.12-$0.16
Low estimate-$0.03-$0.04-$0.12-$0.16
High estimate-$0.03-$0.04-$0.12-$0.16
No. of analysts1111
Year-ago EPS—-$1.18-$1.351—
Growth—+96.6%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$276.00M$40.00M
Low estimate$0.00$0.00$276.00M$40.00M
High estimate$0.00$0.00$276.00M$40.00M
No. of analysts0011
Year-ago revenue—$0.00$0.00—
Growth————

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MIRA20 companies · 8 funds
Compare MIRA with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ANTXAN2 Therapeutics, Inc.Biotechnology$188M
  • APUSApimeds Pharmaceuticals US, IncBiotechnology$3M
  • IGCIGC Pharma, Inc.Biotechnology$23M
  • MLSSMilestone Scientific Inc.Medical - Instruments & Supplies$23M
  • MODDModular Medical, Inc.Medical - Devices$17M
  • MYOMyomo, Inc.Medical - Devices$35M
  • NNVCNanoViricides, Inc.Biotechnology$30M
  • POCIPrecision Optics Corporation, Inc.Medical - Instruments & Supplies$46M

More Drug Manufacturers - General companies

  • SCLXWScilex Holding CompanyNASDAQ$14M
  • SNPHFSanten Pharmaceutical Co., Ltd.OTC$3.1B
  • SNPHYSanten Pharmaceutical Co., Ltd.OTC$3.7B
  • SNYSanofiNASDAQ$113.1B
  • SNYNFSanofiOTC$115.1B
  • TGRNFTong Ren Tang Technologies Co. Ltd.OTC$704M
  • VRBCFVirbac S.A.OTC$2.9B
  • ABBVAbbVie Inc.NYSE$505.5B
  • ALPMFAstellas Pharma Inc.OTC$28.1B
  • ALPMYAstellas Pharma Inc.OTC$29.2B
  • AMGNAmgen Inc.NASDAQ$240.1B
  • AMRNAmarin Corporation plcNASDAQ$233M

ETFs holding MIRA Pharmaceuticals, Inc.

% of the fund

  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • IWCiShares Micro-Cap ETF$1.2B in assets0.01%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets
  • VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets
  • VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets
  • VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets0.00%

Largest holders first, then the funds most concentrated in MIRA.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold MIRA Pharmaceuticals, Inc., and how their positions are changing. At a $24.8M market value, institutional positions materially move MIRA Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by MIRA Pharmaceuticals, Inc. executives and directors. Shares of MIRA Pharmaceuticals, Inc. have traded between $0.73 and $2.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for MIRA Pharmaceuticals, Inc.. Coverage tracks MIRA Pharmaceuticals, Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of MIRA Pharmaceuticals, Inc.

MIRA Analysis
Fair
Past1
Growth2
Health5
Profit1
Value1

News

Latest Market News